Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

Supplemental Table 2. Odds ratios and 95% confidence intervals comparing IGA 0/1[a] and IGA 0[b] responses at week 24 between each guselkumab group and placebo within patient subgroups defined by baseline demographics, disease characteristics, and DMARD use at baseline among pooled DISCOVER-1 and DISCOVER-2 patients with ≥3% BSA with PsO & IGA ≥2 at baseline. Prior to Week 24, patients meeting treatment failure criteria were considered non-responders. Missing data through Weeks 24 and 52 were imputed as non-response.

	IGA 0/1 Response[a]		IGA 0 Response[b]	
	Odds Ratio (95% CI)		Odds Ratio (95% CI)	
	GUS 100 mg Q4W	GUS 100 mg Q8W	GUS 100 mg Q4W	GUS 100 mg Q8W
All patients	11.0 (7.3, 16.5)	8.9 (6.0, 13.5)	12.9 (7.7, 21.5)	10.3 (6.1, 17.3)
Sex				
Male	14.6 (8.2, 26.0)	10.5 (6.0, 18.4)	17.1 (7.9, 37.4)	13.3 (6.1, 29.1)
Female	7.9 (4.4, 14.2)	7.4 (4.1, 13.5)	10.1 (5.0, 20.2)	8.4 (4.2, 17.1)
BMI (kg/m²)				
<25	10.1 (4.5, 22.6)	8.7 (3.9, 19.1)	11.3 (4.0, 31.8)	11.7 (4.2, 32.7)
25 to <30	11.2 (5.6, 22.6)	9.7 (4.9, 19.4)	16.0 (6.9, 37.1)	10.8 (4.7, 24.8)
≥30	11.5 (6.0, 22.1)	8.6 (4.4, 16.6)	12.2 (5.2, 28.5)	9.3 (3.9, 22.1)
PsA duration (years)				
<1	8.0 (2.7, 23.6)	9.8 (3.4, 28.6)	6.6 (2.0, 22.5)	9.6 (2.9, 31.9)
≥1 to <3	12.0 (5.3, 27.2)	8.6 (3.9, 18.8)	10.7 (4.3, 27.0)	7.8 (3.1, 19.7)
≥3	12.1 (7.0, 20.8)	9.1 (5.3, 15.7)	17.6 (8.4, 36.7)	12.3 (5.8, 26.0)
BSA affected by psoriasis (%)				
≥3 to <10	6.8 (3.6, 13.1)	7.2 (3.8, 13.7)	9.3 (4.2, 20.6)	9.4 (4.3, 20.6)
≥10 to <20	8.1 (3.8, 17.3)	5.9 (2.7, 12.9)	9.6 (3.7, 24.8)	6.8 (2.6, 18.2)
≥20	24.6 (11.5, 52.8)	15.9 (7.6, 33.2)	24.1 (9.0, 64.7)	16.4 (6.1, 43.9)
CRP (mg/dL)				
<1	9.8 (5.5, 17.2)	7.9 (4.5, 13.9)	11.6 (5.7, 23.3)	10.3 (5.1, 21.0)
1 to <2	12.9 (5.2, 31.8)	7.6 (3.1, 18.8)	9.4 (3.0, 29.3)	9.9 (3.1, 31.9)
≥2	11.9 (5.4, 26.4)	12.5 (5.7, 27.3)	20.0 (7.2, 55.2)	10.7 (3.9, 29.2)
PASI score at baseline (0-72)				
<12	7.8 (4.8, 12.8)	7.2 (4.4, 11.7)	9.1 (5.1, 16.4)	8.4 (4.7, 15.1)
≥12 to <20	20.0 (7.1, 55.8)	13.9 (4.9, 39.7)	18.5 (5.1, 67.0)	13.0 (3.5, 48.7)
≥20	22.3 (7.5, 66.3)	14.8 (5.0, 43.5)	NC (NC, NC)	NC (NC, NC)
csDMARD/MTX use				
None	21.1 (9.7, 46.1)	10.3 (5.1, 20.7)	20.1 (7.9, 51.0)	10.5 (4.2, 26.5)
Any csDMARD	8.8 (5.3, 14.4)	8.3 (5.0, 13.7)	10.4 (5.6, 19.4)	10.3 (5.5, 19.3)
MTX	9.2 (5.5, 15.4)	8.1 (4.8, 13.8)	10.6 (5.5, 20.2)	10.3 (5.3, 19.8)

[a]IGA psoriasis score of 0 (cleared) or 1 (minimal) and ≥2-grade reduction from baseline in the IGA psoriasis score among patients with ≥3% BSA with psoriasis & IGA ≥2 at baseline

[b]IGA psoriasis score of 0 and ≥2-grade reduction from baseline in the IGA psoriasis score among patients with ≥3% BSA with psoriasis & IGA ≥2 at baseline

BMI=Body mass index, BSA=Body surface area, CI=confidence interval, CRP=C-reactive protein, csDMARD=Conventional synthetic disease-modifying antirheumatic drug, GUS=Guselkumab, IGA=Investigator's Global Assessment, MTX=Methotrexate, PASI=Psoriasis Area and Severity Index, PsA=Psoriatic arthritis, PsO=psoriasis, Q4W/Q8W=every four weeks/every eight weeks